BriaCell Reveals P-II Trial Data of Bria-IMT Regimen for Metastatic Breast Cancer
Shots:
- BriaCell has reported P-II trial data comparing Bria-IMT + check point inhibitors (CPI) to Trodelvy's historical data in heavily pre-treated pts (n=54) with late-stage metastatic breast cancer
- 37 HR+ breast cancer pts of P-II trial were treated with the ongoing pivotal P-III (BRIA-ABC) trial formulation of Bria-IMT, showing favorable survival data
- Trial showed 25/37 pts depicted an mOS of 17.3 vs 14.4mos., while pts with triple negative breast cancer (TNBC) showed an mOS of 11.4 vs 11.8mos. compared to single agent CT pts having mOS of 11.3 & 6.9mos., respectively
Ref: Globenewswire | Image: BriaCell
Related News:- Telix Pharmaceuticals Reports Preliminary P-II (IPAX-Linz) Trial Data of TLX101 to Treat Glioma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
